<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3833">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363437</url>
  </required_header>
  <id_info>
    <org_study_id>2020-04-12</org_study_id>
    <nct_id>NCT04363437</nct_id>
  </id_info>
  <brief_title>COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19</brief_title>
  <acronym>COMBATCOVID19</acronym>
  <official_title>COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most prevalent complication of COVID-19 infection is respiratory failure from severe&#xD;
      acute respiratory syndrome (SARS), the leading cause of mortality. There is increasing&#xD;
      indication that the decompensation in severe COVD-19 infection may be due to a cytokine storm&#xD;
      syndrome. This hyperinflammatory syndrome results in a fulminant and fatal hypercytokinemia&#xD;
      and multiorgan failure.&#xD;
&#xD;
      Approximately 15% of patients with COVID-19 infection are hospitalized and 20-30% of these&#xD;
      hospitalized patients require ICU care and/or mechanical ventilation. Overall mortality in&#xD;
      hospitalized patients is approximately 20-25%. There is significant interest in therapies&#xD;
      that can be given upstream to reduce the rate of mechanical ventilation and thus mortality.&#xD;
&#xD;
      We hypothesize that treatment with colchicine in COVID-19 moderate-severe patients may&#xD;
      decrease the risk of progression into ARDS requiring increased oxygen requirements,&#xD;
      mechanical ventilation, and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, completely randomized, open labeled, controlled study. Patients will be&#xD;
      randomized into two groups (A and B). Patients of group A will be treated under what is&#xD;
      considered current standard of care at Maimonides Medical Center while group B patients will&#xD;
      receive colchicine in addition to standard of care.&#xD;
&#xD;
      Treatment arm&#xD;
&#xD;
      In addition to the local standard of care for COVID 19 patients, the patient will receive&#xD;
      colchicine PO as such:&#xD;
&#xD;
        -  Loading dose of 1.2 mg followed by 0.6mg after 2 hours if without significant&#xD;
           gastrointestinal symptoms (day 1)&#xD;
&#xD;
        -  The next day 0.6mg bid for 14 days or until discharge&#xD;
&#xD;
      Patients who are on HMG-Co A Reductase Inhibitors (atorvastatin, fluvastatin, pravastatin,&#xD;
      simvastatin), fibrates, genfibrozil, amiodarone, dronedarone or digoxin should have the&#xD;
      colchicine dosage reduced to a loading dose of 0.6mg followed by 0.3mg after two hours (day&#xD;
      1) followed by 0.3mg BID for 14 days or until discharge.&#xD;
&#xD;
      If patients have significant gastrointestinal symptoms after loading, the dosage may be&#xD;
      reduced to 0.3mg BID for the rest of the 14 day course or until discharge. If&#xD;
      gastrointestinal symptoms continue, the medication should then be discontinued. Patients who&#xD;
      experience sensory motor neuropathy, or symptoms and laboratory findings consistent with&#xD;
      rhabdomyolysis should prompt immediate discontinuation of the drug. If renal function&#xD;
      deteriorates during the treatment course and CrCl &lt;30ml/min, colchicine should also be&#xD;
      discontinued.&#xD;
&#xD;
      Control arm Usual medical therapy (can include medications such as hydroxychloroquine,&#xD;
      azithromycin)&#xD;
&#xD;
      Patients should NOT receive, Remdesivir, IL-6 inhibitors (Tociluzimab, Sarilumab), JAK&#xD;
      inhibitors, IL-1 inhibitors, or other immunomodulators for COVID-19 before randomization.&#xD;
      Since the primary clinical endpoint is progression of disease, if the patient requires beyond&#xD;
      8L nasal cannula, eg. high flow O2 or mechanical ventilation, the primary clinical endpoint&#xD;
      is met and the above experimental medications will be permitted. To rephrase, the patient&#xD;
      will be allowed, Remdesivir, IL-6 inhibitors and other immunomodulators if then deemed&#xD;
      medically necessary by the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2020</start_date>
  <completion_date type="Anticipated">June 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who will require mechanical ventillation</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum CRP</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum troponin elevation</measure>
    <time_frame>through study completion, estimated 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Colchine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.</description>
    <arm_group_label>Colchine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Males and females &gt;=18 years of age&#xD;
&#xD;
          -  Willing and able to provide written informed consent prior to performing study&#xD;
             procedures&#xD;
&#xD;
          -  Currently hospitalized and requiring medical care for COVID-19&#xD;
&#xD;
          -  Significant COVID-19 symptom, or judged by the treating provider to be at high risk of&#xD;
             progression to severe COVID-19 infection&#xD;
&#xD;
          -  Significant COVID-19 symptoms are defined by one or more of the following:&#xD;
&#xD;
               1. Dyspnea&#xD;
&#xD;
               2. Respiratory frequency ≥ 30/min&#xD;
&#xD;
               3. Blood oxygen saturation ≤ 93%&#xD;
&#xD;
          -  AND one or more of the following: (positive PCR test or positive antibodies) or&#xD;
             (CT/Chest X-ray consistent with COVID19 infection) or (anosmia).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement of oxygen supplementation &gt;8L nasal cannula&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to colchicine&#xD;
&#xD;
          -  Patient currently in shock or with hemodynamic instability requiring pressors&#xD;
&#xD;
          -  History of cirrhosis&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5X upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Patients with severe renal disease, CrCl &lt;30ml/min&#xD;
&#xD;
          -  Patients requiring invasive mechanical ventilation at screening or Clinical estimation&#xD;
             that the patient will require mechanical respiratory support within 24 hours&#xD;
&#xD;
          -  Patient is currently taking colchicine for other indications (gout or Familial&#xD;
             Mediterranean Fever)&#xD;
&#xD;
          -  Patient received Remdesivir, Sarilumab, Tociluzimab, Lopinavir/Ritonavir or other&#xD;
             immunomodulator given for COVID-19 treatment (Note: Convalescent plasma infusion is&#xD;
             not an exclusion)&#xD;
&#xD;
          -  Patient is on (and cannot discontinue) a strong CYP3A4 inhibitor (eg clarithromycin,&#xD;
             indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,&#xD;
             telithromycin, atazanavir), a moderate CYP3A4 inhbitor (eg diltiazem, verapamil,&#xD;
             fluconazole, amprenavir, aprepitant, fosamprenavir) or a P-gp Inhibitor (eg&#xD;
             cyclosporine, ranolazine)&#xD;
&#xD;
          -  Patient is undergoing chemotherapy for cancer&#xD;
&#xD;
          -  Patient is considered by the investigator, for any reason, to be unsuitable candidate&#xD;
             for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix Yang, MD</last_name>
    <phone>718-283-6667</phone>
    <email>fyang@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonios Likourezos, MA, MPH</last_name>
    <email>alikourezos@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Yang, MD</last_name>
      <phone>718-283-6667</phone>
      <email>fyang@maimonidesmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Antonios Likourezos, MPH</last_name>
      <email>alikourezos@maimonidesmed.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colchicine</keyword>
  <keyword>anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

